The current best option we have for combating heart disease and lowering cholesterol are monoclonal antibodies (PCSK9 inhibitors), and a similar trajectory is developing with sarcopenia and obesity biologics (Bimagrumab).
The opportunity for manufacturing innovation is growing, as the next generation of monoclonal antibodies are even more difficult to produce at scale.
If you're more interested in this person's work, his website is here: https://www.iku.bio/